History

IGF-1 DES was isolated in the late 1980s to early 1990s from natural sources including bovine colostrum, human brain, and porcine uterus, where it arises from post-translational cleavage of full-length IGF-1. Francis and colleagues characterized the truncated form from bovine colostrum in 1988, comparing its sequence and biological activity to intact IGF-1, and Ballard and co-workers later reviewed it as a distinct, more potent variant. Much of the foundational work overlaps with the Australian groups that also developed the related long-acting analog LR3-IGF-I.

IGF-1 DES is a real, well-characterized variant of insulin-like growth factor 1 (IGF-1) that is shorter than the native hormone and more potent in the lab. It is sold “for research use only” and promoted for muscle and fat loss, but no human trial supports any of those uses.

What it is

Native IGF-1 is a 70-amino-acid hormone the body makes largely in response to growth hormone. IGF-1 DES — short for des(1-3)IGF-I — is a 67-residue version missing the first three amino acids at one end (the Gly-Pro-Glu tripeptide). It is not purely a lab invention: it occurs naturally and was first isolated from bovine colostrum, human brain, and porcine uterus, where it forms when full-length IGF-1 is clipped.

Losing that short tail — specifically the glutamic acid at position 3 — sharply weakens its grip on IGF-binding proteins (IGFBPs), the carriers that normally hold most circulating IGF-1 inactive. With less of it tied up, the DES form is freer to engage the IGF-1 receptor. In cell culture it is reported to be more potent than intact IGF-1 at driving growth and proliferation; a frequently cited “~10x” figure traces to in-vitro work and is best read as an order-of-magnitude lab observation, not a fixed constant. Importantly, it hits the same receptor and the same anabolic signaling pathways (PI3K-Akt and MAPK) as ordinary IGF-1 — it is a higher-availability version of a known ligand, not a new mechanism.

One commonly repeated number — a roughly 20-30 minute half-life — comes from vendor and secondary sources, not a confirmed human pharmacokinetic study, and should be treated as unverified.

The claims

Marketing material claims IGF-1 DES builds muscle, accelerates fat loss, and supports recovery and tissue repair, often citing its higher potency relative to native IGF-1 as if that potency had been demonstrated to translate into human results.

What the evidence actually shows

The mechanism is real, and the preclinical anabolic data is genuine. In a 1992 rat study, des(1-3)IGF-I and the related LR3-IGF-I were about 2.5-fold more potent than intact IGF-1 at reversing muscle wasting and nitrogen loss in dexamethasone-treated rats. A 1996 review documents the truncated form’s heightened in-vitro potency and reduced IGFBP binding, with anabolic effects noted especially in gut tissue in animals.

But that is where the evidence stops. There appear to be no peer-reviewed human efficacy or safety trials of IGF-1 DES for weight loss, muscle building, or metabolic disease, and no ClinicalTrials.gov registration or published human trial under the DES name. The only consistent human-relevant literature is anti-doping analytical chemistry — methods developed to detect des(1-3)IGF-I (and LongR3-IGF-I) in human plasma — which describes how to find the substance in people, not what it does for them.

It is worth keeping two things separate. Full-length recombinant IGF-1 (mecasermin, brand name Increlex) is an approved drug for severe primary IGF-1 deficiency. That approval is for a different molecule and does not extend to the DES variant. Animal potency does not reliably predict human results, and as of mid-2026 the human evidence for IGF-1 DES is best described as absent, not merely thin.

Legal and regulatory status

IGF-1 DES is not an approved drug anywhere and holds no marketing authorization from the FDA, EMA, or any other regulator for weight loss, muscle, or metabolic use. It is sold as a “research use only” chemical, a label that restricts lawful sale to bona fide laboratory research and is not a green light for human use.

In sport, IGF-1 and its analogues are prohibited at all times — in and out of competition — under the World Anti-Doping Agency’s Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which explicitly covers “IGF-1, mecasermin, and its analogues.” USADA states that all forms of exogenous IGF-1 are prohibited at all times, and WADA-accredited detection literature specifically names des(1-3)IGF-I and LongR3-IGF-I as targeted analogues. This is a ban, not monitoring. (For contrast, GLP-1 receptor agonists such as semaglutide and tirzepatide are not prohibited; they were placed on WADA’s 2026 Monitoring Program as of 1 January 2026.)

Safety

There is no established human safety profile for IGF-1 DES — no dosing data, no long-term data, and no controlled human safety studies for the DES form. Any claim that it is “safe” is extrapolation, not evidence.

The mechanistically expected risks come from IGF-1 biology in general, not from DES-specific trials. Because IGF-1 signaling overlaps with insulin activity, hypoglycemia (low blood sugar) is a plausible risk. Because IGF-1 signaling is mitogenic, and chronically elevated IGF-1 is epidemiologically linked to certain cancers, a more bioavailable analog raises a theoretical tumor-promotion concern. Organ or tissue overgrowth and disrupted glucose handling are also plausibility-based cautions. None of these are measured DES outcomes. On top of that, “research use only” material is not pharmaceutical-quality and carries no assurance of identity, purity, sterility, or endotoxin control. None of this is medical advice.

Bottom line

IGF-1 DES is a real, well-characterized truncated variant of IGF-1 with strong preclinical anabolic data in rodents and cell culture and greater in-vitro potency than the intact hormone. But it has no approved status anywhere and no human clinical trial evidence for weight loss, muscle, or metabolic use, and it is WADA S2-prohibited at all times. Its human efficacy and safety are unestablished — honestly, the human evidence is absent. The hype runs far ahead of what has actually been shown.

Evidence grade: Animal only.